Drug survival of infliximab and adalimumab in inflammatory bowel disease

被引：0
|
作者：
Asadipour, Erfan [1 ]
Kargar, Mona [2 ]
机构：
[1] Univ Tehran Med Sci, Fac Pharm, Dept Clin Pharm, Tehran, Iran
[2] Univ Tehran Med Sci, Res Ctr Rational Use Drugs, Tehran, Iran
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2020年 / 42卷 / 06期
关键词：
THERAPY;
D O I：
10.1007/s11096-020-01151-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1521 / 1523
页数：3
相关论文
共 50 条
  • [1] Drug survival of infliximab and adalimumab in inflammatory bowel disease
    Erfan Asadipour
    Mona Kargar
    International Journal of Clinical Pharmacy, 2020, 42 : 1521 - 1523
  • [2] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Mayte Gil-Candel
    Juan José Gascón-Cánovas
    Elena Urbieta-Sanz
    Lorena Rentero-Redondo
    María Onteniente-Candela
    Carles Iniesta-Navalón
    International Journal of Clinical Pharmacy, 2020, 42 : 500 - 507
  • [3] Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease
    Gil-Candel, Mayte
    Gascon-Canovas, Juan Jose
    Urbieta-Sanz, Elena
    Rentero-Redondo, Lorena
    Onteniente-Candela, Maria
    Iniesta-Navalon, Carles
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (02) : 500 - 507
  • [4] Uptake of drug monitoring of infliximab and adalimumab in inflammatory bowel disease in Australia
    Janko, N.
    Little, R. D.
    Sparrow, M. P.
    Gibson, P. R.
    Ward, M. G.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 136 - 137
  • [5] Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease
    Shannon Chang
    Stephen Hanauer
    Current Treatment Options in Gastroenterology, 2017, 15 (1) : 53 - 70
  • [6] The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease
    Seow, C. H.
    Leung, Y.
    Vande Casteele, N.
    Afshar, E. Ehteshami
    Tanyingoh, D.
    Bindra, G.
    Stewart, M. J.
    Beck, P. L.
    Kaplan, G. G.
    Ghosh, S.
    Panaccione, R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (10) : 1329 - 1338
  • [7] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [8] Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab
    Khan, M.
    Heetun, Z.
    Moloney, J.
    Courtney, G.
    Aftab, A. R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S73 - S74
  • [9] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A. S.
    van den Brink, G. R.
    Ponsioen, C.
    Mathot, R.
    Loewenberg, M.
    D'Haens, G. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
  • [10] PREDICTORS OF PRIMARY NON-RESPONSE AND DRUG DURABILITY FOR ADALIMUMAB AND INFLIXIMAB IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
    Davidson, Nicole
    Morris, Grant
    Wright, Molly
    Brock, Guy
    Boyle, Brendan
    Dotson, Jennifer
    Michel, Hilary
    Maltz, Ross
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S73 - S73
12345